
==== Front
Esophagus
Esophagus
Esophagus
1612-9059
1612-9067
Springer Nature Singapore Singapore

38844704
1069
10.1007/s10388-024-01069-5
Original Article
Two onset types of achalasia and the long-term course to diagnosis
Kurosugi Akane 1
http://orcid.org/0000-0001-5314-9325
Matsumura Tomoaki matsumura@chiba-u.jp

1
Sonoda Michiko 1
Kaneko Tatsuya 1
Takahashi Satsuki 1
Okimoto Kenichiro 1
Akizue Naoki 1
Ohyama Yuhei 1
Mamiya Yukiyo 1
Nakazawa Hayato 1
Horio Ryosuke 1
Goto Chihiro 1
Ohta Yuki 1
Taida Takashi 1
Kikuchi Atsuko 4
Fujie Mai 4
Murakami Kentaro 2
Uesato Masaya 2
Ozawa Yoshihito 3
Kato Jun 1
Matsubara Hisahiro 2
Kato Naoya 1
1 https://ror.org/01hjzeq58 grid.136304.3 0000 0004 0370 1101 Department of Gastroenterology, Graduate School of Medicine, Chiba University, Inohana 1-8-1, Chiba, 260-8670 Japan
2 https://ror.org/01hjzeq58 grid.136304.3 0000 0004 0370 1101 Department of Frontier Surgery, Graduate School of Medicine, Chiba University, Chiba, Japan
3 https://ror.org/0126xah18 grid.411321.4 0000 0004 0632 2959 Department of Clinical Engineering Center, Chiba University Hospital, Chiba, Japan
4 https://ror.org/01hjzeq58 grid.136304.3 0000 0004 0370 1101 Clinical Research Center, Chiba University, Chiba, Japan
6 6 2024
6 6 2024
2024
21 4 546551
25 1 2024
28 5 2024
© The Author(s) 2024
2024
https://creativecommons.org/licenses/by/4.0/ Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
Background

Recently, the incidence of achalasia has been increasing, but its cause remains unknown. This study aimed to examine the initial symptoms and the course of symptoms and to find new insights into the cause and course of the disease.

Methods

Altogether, 136 patients diagnosed with achalasia by high-resolution manometry (HRM) were enrolled. Questionnaires and chart reviews were conducted to investigate the initial symptoms, time from onset to diagnosis, and comorbidities, as well as the relationship between HRM results, time to diagnosis, and symptom severity.

Results

In total, 67 of 136 patients responded to the questionnaire. The median ages of onset and diagnosis were 42 and 58 years, respectively. The median time from onset to diagnosis was 78.6 months, with 25 cases (37.3%) taking > 10 years to be diagnosed. The symptom onset was gradual and sudden in 52 (77.6%) and 11 (16.4%) patients, respectively. Of the 11 patients with acute onset, three (27.3%) developed anhidrosis at the same time. There was no correlation between the time from onset to diagnosis and esophageal dilatation, resting LES pressure, or mean integrated relaxation pressure (IRP). No correlation was also found between the degree of symptoms and resting LES pressure or IRP.

Conclusion

Esophageal achalasia can have acute or insidious onsets. This finding may help to elucidate the cause of achalasia.

Keywords

Esophageal achalasia
High-resolution manometry
Anhidrosis
issue-copyright-statement© The Japan Esophageal Society 2024
==== Body
pmcIntroduction

Achalasia is an esophageal motility disorder associated with impaired relaxation and peristalsis of the lower esophageal sphincter (LES) [1]. Its annual incidence is approximately 1.6 cases per 100,000 persons, with a prevalence of 10 cases per 100,000 persons, making it a rare disease; however, its incidence and prevalence have been increasing recently [2, 3]. Regarding the treatment, intrasphincteric injection of botulinum toxin [4], balloon dilatation [5], surgical myotomy [6], and oral endoscopic myotomy (POEM) [7] are performed to release the functional obstruction at the LES level, but these procedures are all merely coping strategies. The cause of achalasia has been suggested to be autoimmune disease [8, 9], viral infections [10, 11], and allergic diseases [12, 13], but the cause has not yet been elucidated. The reason why the cause of achalasia has yet to be elucidated, despite various studies to date, may be due to its mode of onset and long-term course of the disease leading up to diagnosis. Achalasia generally has a insidious onset with gradual damage to LES neurons [14, 15]. Given that the sphincter loses its ability to relax over time [15], the underlying cause of LES neuron damage may have disappeared by the time of diagnosis. Therefore, the present study aimed to examine in detail the initial symptoms and the course of symptoms and to find new insights into the cause and course of the disease.

Materials and methods

Design and patients

This single-center, retrospective cohort study was conducted according to the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guidelines [16]. Among the 804 patients who underwent high-resolution manometry (HRM) testing at Chiba University Hospital between March 2011 and August 2022, we enrolled 136 patients diagnosed with achalasia. This study was approved by the Chiba University Ethics Committee (approval number 4063).

Questionnaire

The questionnaires were mailed to all patients. The questionnaire included information on medical history, allergies, medications, age at onset, initial symptoms, type of onset (acute or insidious onset), and age at the time of diagnosis, as well as a space for free answers. All patients completed the frequency scale for the symptoms of GERD (FSSG) questionnaire before HRM testing. The FSSG questionnaire consists of 12 items categorized into two domains, with each item scored from 0 (never) to 4 (always). Dysmotility-like symptoms (dyspepsia score), the first domain, are calculated by summing the scores (range: 0–28) for items 1, 4, 6, 7, 9, 10, and 12. Acid reflux-related symptoms (reflux score), the second domain, involved summing the scores (range: 0–20) for items 2, 3, 5, 8, and 11 [17]. Acute onset was defined as a sudden onset of symptoms with a definite date and time of onset; otherwise, it was defined as an insidious onset.

HRM

The HRM system used was the Diversatek system (Boulder, Colorado, USA) with 32 pressure and 16 impedance sensors. Patients were asked to swallow 5 mL of water 10 times in the supine or semi-Fowler's position. Achalasia was diagnosed according to the Chicago Classification; version 4.0 was used for diagnosis after 2021 and version 3.0 before that date [18, 19]. Resting LES pressure was defined as LES pressure for 30 s without swallowing.

Endoscopic findings

All patients underwent upper gastrointestinal endoscopy. For diagnosing eosinophilic esophagitis (EoE), esophageal multiple mucosal biopsies were performed with or without endoscopic findings, and EoE was diagnosed if the eosinophilic infiltrate was ≥ 15/HPF [20].

Statistical analysis

Baseline data are presented as the median and interquartile range. The data were analyzed using the GraphPad Prism software (version 8; Massachusetts, USA). Comparisons of the two groups were performed using Mann–Whitney U tests. The correlation coefficient was calculated using Spearman’s rank correlation coefficient. Differences with p < 0.05 were considered significant. For comparisons among the three groups, the significance level was set at 0.017 (0.05/3) and multiplicity was adjusted using the Bonferroni method.

Results

Study flow diagram and patient demographics

Figure 1 shows the flowchart of patient enrolment. In total, 67 (49.3%) of 136 patients with esophageal achalasia responded to the questionnaire. The patients’ background characteristics are shown in Table 1. There were 31 males and 36 females, and the median age of diagnosis of 58 years. Regarding the medical history, two cases had EoE (out of 31 patients who underwent biopsy) and one had scleroderma. No patient had a family history. The median age of onset was 42 years.Fig. 1 Flowchart of patient enrolment. HRM: high-resolution manometry

Table 1 Clinical characteristics of patients with achalasia

Clinical characteristics	n = 67	
Sex (male/female)	31/36	
Age at onset (years), median (IQR)	42 (31.8–57.8)	
Age at diagnosis (years), median (IQR)	58 (41.3–73.3)	
Comorbidity	
 Hypertension, n (%)	15 (22.7%)	
 Diabetes mellitus, n (%)	5 (7.5%)	
 Eosinophilic esophagitis, n* (%)	2 (6.1%)	
 Scleroderma, n (%)	1 (1.5%)	
 Anhidrosis, n (%)	3 (4.5%)	
Allergy, n (%)	47 (70.1%)	
 Asthma	5 (7.5%)	
 Atopic dermatitis	7 (10.4%)	
 Pollen allergy	23 (34.3%)	
 Food/Drug allergy	10 (14.9%)	
 Other (e.g., animals)	2 (3.0%)	
HRM results	
 Type I Achalasia, n (%)	38 (56.7%)	
 Type II Achalasia, n (%)	23 (34.8%)	
 Type III Achalasia, n (%)	6 (9.1%)	
 LES resting pressure, median (IQR, mmHg)	43 (31–54.3)	
 IRP, median (IQR, mmHg)	38 (30.6–44.1)	
Data are presented as n (%)

HRM high-resolution manometry, IRP integrated relaxation pressure, LES lower esophageal sphincter, IQR interquartile range

*Of the 31 cases in which esophageal biopsies were performed

Time to diagnosis

Dysphagia accounted for 90% of the initial symptoms, with other symptoms varying from chest pain, heartburn, vomiting, and weight loss (Fig. 2). The median age at the time of diagnosis was 58 years, and the time from onset to diagnosis was 78.6 months. Altogether, 10.4% and 37.3% of the cases were diagnosed within 1 year of onset and > 10 years later, respectively (Fig. 3A). There were two patients who could not provide a definitive answer regarding the time of onset (Fig. 3A).Fig. 2 Symptoms at the first disease onset

Fig. 3 A Time from onset to diagnosis. B Time from onset to diagnosis by achalasia type. C Correlation between the time from onset to diagnosis and LES pressure at the time of diagnosis. D Correlation between the time from onset to diagnosis and IRP at the time of diagnosis. E Correlation between degree of symptoms and LES pressure at the time of diagnosis. F Correlation between degree of symptoms and IRP at the time of diagnosis. LES, lower esophageal sphincter; IRP, integrated relaxation pressure; FSSG, the frequency scale for the symptoms of GERD

Differences by achalasia type

The median time from onset to diagnosis by achalasia type was 91.3 months for Type I, 72.5 months for Type II, and 7.1 months for Type III. Type III cases were diagnosed significantly earlier than Type I and II cases (p = 0.014, p = 0.006) (Fig. 3B). Correlation analyses of HRM results (LES resting pressure, IRP) at diagnosis and time from onset to diagnosis are shown in Figs. 3C and D. Neither LES resting pressure (r = 0.24, p = 0.07) nor IRP value (r = − 0.09, p = 0.51) correlated with time to diagnosis. (Figs. 3C and D). Correlation analyses between HRM results (LES resting pressure, IRP) at diagnosis and degree of symptoms are shown in Figs. 3E and F. No correlation was found between HRM results and symptom severity (Figs. 3E and F).

Onset types of achalasia

Results for type of onset are shown in Fig. 4. There were two types of onsets: acute onset in 16.4% of patients and insidious onset in 77.6%. Four patients were unable to provide a clear answer regarding the type of onset (Fig. 4). Three patients (27.3%) had anhidrosis in the acute onset group; two of the three patients were subsequently examined by a neurologist and diagnosed with postacute onset autonomic neuropathy, with one of them receiving steroid pulse therapy, but the effect was inadequate.Fig. 4 Pattern of the beginning of symptoms

Discussion

The present study examined the form of onset of achalasia and the process leading to the diagnosis of the disease. Achalasia is considered a slowly progressive disease [1]. However, after a detailed survey using questionnaires, we found that there are acute-onset cases of achalasia. Additionally, several cases with acute-onset type also had anhidrosis at the same time. In the present study, we conducted a detailed investigation from the onset of symptoms to diagnosis. The results revealed that there were differences in the types of onsets of symptoms and that it took a long time to reach a diagnosis, with a median time of 78 months. Additionally, some patients were suspected of having a psychiatric disorder and were seen by multiple departments, including a psychiatrist. The existence of an acute-onset type of achalasia has been reported in recent years [21, 22]. Both reports were of onset after COVID-19 infection, and acute-onset achalasia may have been due to viral infection.

Anhidrosis is a disorder in which an individual does not sweat even in an environment that promotes sweating (high temperature and humidity) [23]. There are congenital and acquired forms of anhidrosis, and the causes of acquired generalized anhidrosis are classified into secondary sweating disorders caused by abnormalities of the eccrine sweat glands and sympathetic nerves, drugs, acquired idiopathic generalized anhidrosis, and autoimmune diseases such as autoimmune autonomic ganglionopathy [24]. Two cases of anhidrosis in this study were diagnosed as autoimmune autonomic ganglionopathy. Autoimmune autonomic ganglionopathy is also an autoimmune disorder of unknown etiology, characterized by a variety of autonomic nervous system symptoms such as orthostatic hypotension, urinary retention, and sweating abnormalities. Digestive symptoms such as constipation and achalasia have been reported as complications. It has been reported that 14% of patients with autoimmune autonomic ganglionopathy had prodromal symptoms, such as flu-like symptoms, shortly before the onset of autonomic symptoms [25]. This may support an association between acute-onset achalasia and viral infection, including associated autonomic symptoms. One of these patients was referred to a neurologist who diagnosed the patient with a sequela of acute autonomic neuropathy. Subsequently (approximately 1 month after disease onset), steroid pulse therapy was performed, but no improvement was seen, probably because a long time had elapsed between onset and treatment. However, the present results suggest that there may be cases of esophageal achalasia, especially with autonomic neuropathy, for which medical treatment is effective. Early therapeutic intervention may have the potential to improve symptoms. Furthermore, it is also known that there are cases of pseudo-achalasia secondary to malignant disease when patients have acute onset of symptoms [26]. Considering this point, patients with acute onset of symptoms should be examined quickly.

Most coherent reports of achalasia have come from Europe and the United States [27, 28]. In Japan, Sato et al. reported 385 cases of achalasia nationwide, with a prevalence rate of 7.0 per 100,000 persons, similar to that reported in Western countries [29]. The types of disease onset and time to diagnosis examined in the present study have not been investigated. Regarding the time from symptom onset to diagnosis, Niebisch et al. reported an average of 25 months (approximately 2 years) from symptom onset to diagnosis in Germany [30]. They noted that early achalasia is difficult to diagnose by endoscopy alone and that the widespread use of HRM is useful for early diagnosis. Eckardt et al. also studied 87 German cases of achalasia and concluded that the mean symptom duration was 4.7 ± 6.4 years, and that the delay in diagnosis was not due to atypical clinical symptoms but rather to the misinterpretation of typical findings by the consulting physician [31]. Contrarily, our cohort took a median of 78 months (approximately 6.5 years), which is longer than that reported in the German study [30, 31]. This difference may be due to the low application rate of HRM in Japan, which may have affected the time to diagnosis.

The present study has several strengths. First, it is the first report summarizing the two symptoms onset types of achalasia. Second, a detailed survey of patients, rather than a chart review alone, was conducted. Given that it is difficult to conduct a detailed survey based on chart review alone, a questionnaire was mailed along with it and a survey was also conducted in this study. Third, this is the first Asian report describing the time from disease onset to the confirmation of diagnosis. Despite its strengths, this study has several limitations. First, the questionnaire collection rate was low, and not all cases could be investigated. The unresponsive patients were excluded from the study because the information obtained from the chart review alone was not accurate. Second, the sample size, especially for Type III achalasia and anhidrosis, was small. Therefore, results may differ if a large number of cases is included. Third, biopsies for the diagnosis of EoE were not performed in all cases, but in about half. Therefore, this result may contain bias. Fourth, it has been reported in recent years that achalasia without high IPR values exists [32]. The IRP values of the cases included in this study were relatively high (median IRP 38 [30.6–44.1] mm Hg), which may have influenced the correlation between IRP values and time to diagnosis. Fifth, the present work was a single-center, retrospective study; hence, a further study with a larger number of patients at multiple centers are warranted to determine whether similar results can be obtained.

In conclusion, the early diagnosis of achalasia is important for the early improvement of patients’ quality of life and for health economics reasons. Our new findings may help to elucidate the pathogenesis of achalasia in the future.

Acknowledgement

The authors would like to thank Enago (www.enago.jp) for English language review.

Author contributions

Conception and design: TM and AK; acquisition of data: AK, TK, ST, KO, NA, YO, YM, HN, RH, CG, YO, TT, AK, MF, KM, and MU; analysis and interpretation of data: AK and TM; drafting of the manuscript: AK, MS, and TM; critical revision of the manuscript: JK; statistical analysis: AK, TM and YO; study supervision: JK, HM, and NK. All authors have contributed substantially to the design, data collection and analysis, and manuscript editing.

Funding

None declared.

Data availability

The data that support the findings of this study are available from the corresponding author, TM (ORCID, 0000-0001-5314-9325), upon reasonable request.

Declarations

Conflict of interest

None declared.

Ethical statement

All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1964 and later versions. Informed consent or substitute for it was obtained from all patients for being included in the study.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
==== Refs
References

1. Boeckxstaens GE Zaninotto G Richter JE Achalasia Lancet 2014 383 83 93 10.1016/S0140-6736(13)60651-0 23871090
Boeckxstaens GE, Zaninotto G, Richter JE. Achalasia. Lancet. 2014;383:83–93.23871090 10.1016/S0140-6736(13)60651-0
2. Sadowski DC Ackah F Jiang B Achalasia: incidence, prevalence and survival. A population-based study Neurogastroenterol Motil 2010 22 e256 e261 10.1111/j.1365-2982.2010.01511.x 20465592
Sadowski DC, Ackah F, Jiang B, et al. Achalasia: incidence, prevalence and survival. A population-based study. Neurogastroenterol Motil. 2010;22:e256–61.20465592 10.1111/j.1365-2982.2010.01511.x
3. O’Neill OM Johnston BT Coleman HG Achalasia: a review of clinical diagnosis, epidemiology, treatment and outcomes World J Gastroenterol 2013 19 5806 5812 10.3748/wjg.v19.i35.5806 24124325
O’Neill OM, Johnston BT, Coleman HG. Achalasia: a review of clinical diagnosis, epidemiology, treatment and outcomes. World J Gastroenterol. 2013;19:5806–12.24124325 10.3748/wjg.v19.i35.5806
4. Vaezi MF Richter JE Wilcox CM Botulinum toxin versus pneumatic dilatation in the treatment of achalasia: a randomised trial Gut 1999 44 231 239 10.1136/gut.44.2.231 9895383
Vaezi MF, Richter JE, Wilcox CM, et al. Botulinum toxin versus pneumatic dilatation in the treatment of achalasia: a randomised trial. Gut. 1999;44:231–9.9895383 10.1136/gut.44.2.231
5. Zerbib F Thétiot V Richy F Repeated pneumatic dilations as long-term maintenance therapy for esophageal achalasia Am J Gastroenterol 2006 101 692 697 10.1111/j.1572-0241.2006.00385.x 16635216
Zerbib F, Thétiot V, Richy F, et al. Repeated pneumatic dilations as long-term maintenance therapy for esophageal achalasia. Am J Gastroenterol. 2006;101:692–7.16635216 10.1111/j.1572-0241.2006.00385.x
6. Oelschlager BK Chang L Pellegrini CA Improved outcome after extended gastric myotomy for achalasia Arch Surg 2003 138 490 495 10.1001/archsurg.138.5.490 12742951
Oelschlager BK, Chang L, Pellegrini CA. Improved outcome after extended gastric myotomy for achalasia. Arch Surg. 2003;138:490–5.12742951 10.1001/archsurg.138.5.490
7. Inoue H Minami H Kobayashi Y Peroral endoscopic myotomy (POEM) for esophageal achalasia Endoscopy 2010 42 265 271 10.1055/s-0029-1244080 20354937
Inoue H, Minami H, Kobayashi Y, et al. Peroral endoscopic myotomy (POEM) for esophageal achalasia. Endoscopy. 2010;42:265–71.20354937 10.1055/s-0029-1244080
8. Gaber CE Cotton CC Eluri S Autoimmune and viral risk factors are associated with achalasia: a case-control study Neurogastroenterol Motil 2022 34 e14312 10.1111/nmo.14312 34957646
Gaber CE, Cotton CC, Eluri S, et al. Autoimmune and viral risk factors are associated with achalasia: a case-control study. Neurogastroenterol Motil. 2022;34: e14312.34957646 10.1111/nmo.14312
9. Furuzawa-Carballeda J Aguilar-León D Gamboa-Domínguez A Achalasia–an autoimmune inflammatory disease: a cross-sectional study J Immunol Res 2015 2015 729217 10.1155/2015/729217 26078981
Furuzawa-Carballeda J, Aguilar-León D, Gamboa-Domínguez A, et al. Achalasia–an autoimmune inflammatory disease: a cross-sectional study. J Immunol Res. 2015;2015: 729217.26078981 10.1155/2015/729217
10. Naik RD Vaezi MF Gershon AA Association of achalasia with active varicella zoster virus infection of the esophagus Gastroenterology 2021 161 719 21.e2 10.1053/j.gastro.2021.04.057 33932481
Naik RD, Vaezi MF, Gershon AA, et al. Association of achalasia with active varicella zoster virus infection of the esophagus. Gastroenterology. 2021;161:719-21.e2.33932481 10.1053/j.gastro.2021.04.057
11. Robertson CS Martin BA Atkinson M Varicella-zoster virus DNA in the oesophageal myenteric plexus in achalasia Gut 1993 34 299 302 10.1136/gut.34.3.299 8386130
Robertson CS, Martin BA, Atkinson M. Varicella-zoster virus DNA in the oesophageal myenteric plexus in achalasia. Gut. 1993;34:299–302.8386130 10.1136/gut.34.3.299
12. Furuta GT Liacouras CA Collins MH Eosinophilic esophagitis in children and adults: a systematic review and consensus recommendations for diagnosis and treatment Gastroenterology 2007 133 1342 1363 10.1053/j.gastro.2007.08.017 17919504
Furuta GT, Liacouras CA, Collins MH, et al. Eosinophilic esophagitis in children and adults: a systematic review and consensus recommendations for diagnosis and treatment. Gastroenterology. 2007;133:1342–63.17919504 10.1053/j.gastro.2007.08.017
13. Ghisa M Laserra G Marabotto E Achalasia and obstructive motor disorders are not uncommon in patients with eosinophilic esophagitis Clin Gastroenterol Hepatol 2021 19 1554 1563 10.1016/j.cgh.2020.07.056 32763482
Ghisa M, Laserra G, Marabotto E, et al. Achalasia and obstructive motor disorders are not uncommon in patients with eosinophilic esophagitis. Clin Gastroenterol Hepatol. 2021;19:1554–63.32763482 10.1016/j.cgh.2020.07.056
14. Pandolfino JE Gawron AJ Achalasia: a systematic review JAMA 2015 313 1841 1852 10.1001/jama.2015.2996 25965233
Pandolfino JE, Gawron AJ. Achalasia: a systematic review. JAMA. 2015;313:1841–52.25965233 10.1001/jama.2015.2996
15. Howard PJ Maher L Pryde A Five year prospective study of the incidence, clinical features, and diagnosis of achalasia in Edinburgh Gut 1992 33 1011 1015 10.1136/gut.33.8.1011 1398223
Howard PJ, Maher L, Pryde A, et al. Five year prospective study of the incidence, clinical features, and diagnosis of achalasia in Edinburgh. Gut. 1992;33:1011–5.1398223 10.1136/gut.33.8.1011
16. von Elm E Altman DG Egger M The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies Lancet 2007 370 1453 1457 10.1016/S0140-6736(07)61602-X 18064739
von Elm E, Altman DG, Egger M, et al. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet. 2007;370:1453–7.18064739 10.1016/S0140-6736(07)61602-X
17. Kusano M Shimoyama Y Sugimoto S Development and evaluation of FSSG: frequency scale for the symptoms of GERD J Gastroenterol 2004 39 888 891 10.1007/s00535-004-1417-7 15565409
Kusano M, Shimoyama Y, Sugimoto S, et al. Development and evaluation of FSSG: frequency scale for the symptoms of GERD. J Gastroenterol. 2004;39:888–91.15565409 10.1007/s00535-004-1417-7
18. Yadlapati R Kahrilas PJ Fox MR Esophageal motility disorders on high-resolution manometry: Chicago classification version 4.0© Neurogastroenterol Motil 2021 33 e14058 10.1111/nmo.14058 33373111
Yadlapati R, Kahrilas PJ, Fox MR, et al. Esophageal motility disorders on high-resolution manometry: Chicago classification version 4.0©. Neurogastroenterol Motil. 2021;33:e14058.33373111 10.1111/nmo.14058
19. Kahrilas PJ Bredenoord AJ Fox M International high resolution manometry working group: the Chicago classification of esophageal motility disorders, v3.0 Neurogastroenterol Motil 2015 27 160 174 10.1111/nmo.12477 25469569
Kahrilas PJ, Bredenoord AJ, Fox M, et al. International high resolution manometry working group: the Chicago classification of esophageal motility disorders, v3.0. Neurogastroenterol Motil. 2015;27:160–74.25469569 10.1111/nmo.12477
20. Dellon ES Liacouras CA Molina-Infante J Updated international consensus diagnostic criteria for eosinophilic esophagitis: proceedings of the AGREE conference Gastroenterology 2018 155 1022 3310 10.1053/j.gastro.2018.07.009 30009819
Dellon ES, Liacouras CA, Molina-Infante J, et al. Updated international consensus diagnostic criteria for eosinophilic esophagitis: proceedings of the AGREE conference. Gastroenterology. 2018;155:1022–3310.30009819 10.1053/j.gastro.2018.07.009
21. Samo S Hamo F Hamza A Rapid development of achalasia after SARS-CoV-2 infection: PCR analysis of esophageal muscle tissue Am J Gastroenterol 2024 119 987 990 38265043
Samo S, Hamo F, Hamza A, et al. Rapid development of achalasia after SARS-CoV-2 infection: PCR analysis of esophageal muscle tissue. Am J Gastroenterol. 2024;119:987–90.38265043
22. Wasim AU Khan MW Khan OA Acute-onset achalasia following a recent covid-19 infection: a case report Cureus 2023 15 e38803 37303428
Wasim AU, Khan MW, Khan OA, et al. Acute-onset achalasia following a recent covid-19 infection: a case report. Cureus. 2023;15: e38803.37303428
23. Kageyama R Honda T Tokura Y Acquired idiopathic generalized anhidrosis (AIGA) and its complications: implications for AIGA as an autoimmune disease Int J Mol Sci 2021 22 8389 10.3390/ijms22168389 34445091
Kageyama R, Honda T, Tokura Y. Acquired idiopathic generalized anhidrosis (AIGA) and its complications: implications for AIGA as an autoimmune disease. Int J Mol Sci. 2021;22:8389.34445091 10.3390/ijms22168389
24. Munetsugu T Fujimoto T Oshima Y Revised guideline for the diagnosis and treatment of acquired idiopathic generalized anhidrosis in Japan J Dermatol 2017 44 394 400 10.1111/1346-8138.13649 27774633
Munetsugu T, Fujimoto T, Oshima Y, et al. Revised guideline for the diagnosis and treatment of acquired idiopathic generalized anhidrosis in Japan. J Dermatol. 2017;44:394–400.27774633 10.1111/1346-8138.13649
25. Nakane S Mukaino A Higuchi O A comprehensive analysis of the clinical characteristics and laboratory features in 179 patients with autoimmune autonomic ganglionopathy J Autoimmun 2020 108 102403 10.1016/j.jaut.2020.102403 31924415
Nakane S, Mukaino A, Higuchi O, et al. A comprehensive analysis of the clinical characteristics and laboratory features in 179 patients with autoimmune autonomic ganglionopathy. J Autoimmun. 2020;108: 102403.31924415 10.1016/j.jaut.2020.102403
26. Dimitrios S Nikoletta AT Ioannis K Pseudoachalasia: a systematic review of the literature Esophagus 2020 17 216 222 10.1007/s10388-020-00720-1 31989338
Dimitrios S, Nikoletta AT, Ioannis K, et al. Pseudoachalasia: a systematic review of the literature. Esophagus. 2020;17:216–22.31989338 10.1007/s10388-020-00720-1
27. Samo S Carlson DA Gregory DL Incidence and prevalence of achalasia in central Chicago, 2004–2014, since the widespread use of high-resolution manometry Clin Gastroenterol Hepatol 2017 15 366 373 10.1016/j.cgh.2016.08.030 27581064
Samo S, Carlson DA, Gregory DL, et al. Incidence and prevalence of achalasia in central Chicago, 2004–2014, since the widespread use of high-resolution manometry. Clin Gastroenterol Hepatol. 2017;15:366–73.27581064 10.1016/j.cgh.2016.08.030
28. Gaber CE Eluri S Cotton CC Epidemiologic and economic burden of achalasia in the United States Clin Gastroenterol Hepatol 2022 20 342 52.e5 10.1016/j.cgh.2021.02.035 33652152
Gaber CE, Eluri S, Cotton CC, et al. Epidemiologic and economic burden of achalasia in the United States. Clin Gastroenterol Hepatol. 2022;20:342-52.e5.33652152 10.1016/j.cgh.2021.02.035
29. Sato H Yokomichi H Takahashi K Epidemiological analysis of achalasia in Japan using a large-scale claims database J Gastroenterol 2019 54 621 627 10.1007/s00535-018-01544-8 30607612
Sato H, Yokomichi H, Takahashi K, et al. Epidemiological analysis of achalasia in Japan using a large-scale claims database. J Gastroenterol. 2019;54:621–7.30607612 10.1007/s00535-018-01544-8
30. Niebisch S Hadzijusufovic E Mehdorn M Achalasia—an unnecessary long way to diagnosis Dis Esophagus 2017 30 1 6 10.1093/dote/dow004 28375437
Niebisch S, Hadzijusufovic E, Mehdorn M, et al. Achalasia—an unnecessary long way to diagnosis. Dis Esophagus. 2017;30:1–6.28375437 10.1093/dote/dow004
31. Eckardt VF Köhne U Junginger T Risk factors for diagnostic delay in achalasia Dig Dis Sci 1997 42 580 585 10.1023/A:1018855327960 9073142
Eckardt VF, Köhne U, Junginger T, et al. Risk factors for diagnostic delay in achalasia. Dig Dis Sci. 1997;42:580–5.9073142 10.1023/A:1018855327960
32. Patel P Rogers BD Rengarajan A dentification of achalasia within absent contractility phenotypes on high-resolution manometry: prevalence, predictive factors and treatment outcome Am J Gastroenterol 2024 10.14309/ajg.00000000000000002694 39235290
Patel P, Rogers BD, Rengarajan A, et al. Identification of achalasia within absent contractility phenotypes on high-resolution manometry: prevalence, predictive factors and treatment outcome. Am J Gastroenterol. 2024;20. 10.14309/ajg.00000000000000002694.39235290 10.14309/ajg.00000000000000002694
